Graphene quantum dots rescue angiogenic retinopathy via blocking STAT3/Periostin/ERK signaling.

ABSTRACT:

Background

Pathological retinal angiogenesis resulting from a variety of ocular diseases including oxygen induced retinopathy, diabetic retinopathy and ocular vein occlusion, is one of the major reasons for vision loss, yet the therapeutic option is limited. Multiple nanoparticles have been reported to alleviate angiogenic retinopathy. However, the adverse effect cannot be ignored due to the relatively large scale. Graphene quantum dots (GQDs) have shown potential in drug delivery and have been proved biocompatible. In this study, Graphene quantum dots are extensively investigated for their application in angiogenic retinopathy therapy.

Results

We showed that GQDs were biocompatible nanomaterials in vitro and in vivo. The nanoparticles have a dose-dependent inhibitory effect

SUBMITTER: Zhao N 

PROVIDER: S-EPMC8977040 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature